In April, the FDA warned of risk of secondary cancers in people receiving CAR-T cell therapy. A large Stanford Medicine study finds the risk is low and not related to the CAR-T cells.
A lack of disclosure compounded by insufficient sexual orientation and gender identity data collection by providers can lead to a myriad of challenges in prostate cancer treatment.
The professor of dermatology and genetics was honored with the 2024 Lurie Prize for his studies into the role of long noncoding RNA in health and disease.
In a finding that vastly expands the understanding of tumor evolution, researchers discover genetic biomarkers that can predict the breast cancer subtype a patient is likely to develop.
Stanford scientists illuminate the relationship between adoptively transferred T cells and macrophages and how two immunotherapies may work together to increase their tumor-fighting capabilities.
Thanks to the partnership with Stanford’s Advanced Melanoma Program and Blood and Marrow Transplantation (BMT) & Cellular Therapy Program, Stanford treated the first patient in the world with the newly approved TIL therapy.
The FDA recently approved the first cell-based therapy — widely used in treating blood cancers — for solid tumors. Stanford Medicine treated the first patient with advanced melanoma.
Within the past couple of decades, the field of oncology has witnessed a shift to more curative treatments for patients with lung cancer, with radiation being a key factor in this new trajectory.
Cancer scientists at Stanford and the Children’s Hospital of Philadelphia (CHOP) identified a protein, FOXO1, that improves the survival and function of CAR-T cells, which may lead to more effective CAR-T cell therapies and could potentially expand...
Artificial intelligence algorithms powered by deep learning improve skin cancer diagnostic accuracy for doctors, nurse practitioners and medical students in a study led by the Stanford Center for Digital Health.
Soft tissue sarcomas are rare and difficult to treat. Machine-learning tools designed at Stanford Medicine uncover distinct cellular communities that correlate with prognosis, immunotherapy success.
In honor of the 2024 World Cancer Day theme, “Close the Care Gap,” we highlight a few Stanford cancer researchers working to close the care gap in diverse populations through screening, clinical trials, prevention, and community engagement.
The Stanford Cancer Institute Early Drug Development (EDD) program brings in early-phase clinical trials so cancer patients can have access to innovative treatments that could provide a therapeutic benefit.
Meryl Selig has had a unique experience at the Stanford Cancer Institute (SCI). She began as a patient volunteer in 2009 before being diagnosed with cancer and becoming a patient. She became one of the first patients to receive a novel chimeric...
CAR-T therapy has shown a great benefit in patients with hematologic and lymphatic cancers. However, applying the therapy to solid tumors has proven to be challenging. One of the barriers is T cell exhaustion, where the CAR-T cell becomes...
A Stanford Medicine study identifies an easily measured biophysical property that can identify Type 2 diabetics at increased risk for liver cancer who don’t meet current screening guidelines.
Treatment of metastatic disease is responsible for nearly one-third of the decrease in annual deaths from breast cancer from 1975 to 2019, according to a Stanford Medicine-led study.
Stanford Cancer Institute member Elizabeth Kidd, MD, is developing new tools to facilitate the broader adoption of brachytherapy and ultimately improve outcomes for women facing cervical cancer.
Circulating tumor DNA predicts recurrence and splits disease into two subgroups in Stanford Medicine-led study of Hodgkin lymphoma. New drug targets or changes in treatments may reduce toxicity.
On August 30, 2021, California adopted the Cancer Patients’ Bill of Rights, the first legislation of its kind in the United States. This legislation gives cancer patients inalienable rights to help them achieve access and equity in their care.
A study led by SCI members Summer Han, PhD, and Eunji Choi, PhD, and graduate student Chloe Su found that lung cancer survivors who have never smoked have the same risk as survivors who have smoked of developing secondary primary lung cancer (SPLC),...
Pancreatic cancer is deadly, and its toll is growing. Scientists find that scar tissue around the tumor suggests how long a patient will live after diagnosis.
Stanford is excited to have 26 presenters at this year's ASH Annual Meeting & Exposition. The Stanford Cancer Institute will also be hosting a booth at this year's conference.
During Gastric and Pancreatic Cancer Awareness Month, SCI member George Poultsides discusses his efforts to advance early detection of pancreatic cancer, improve personalized oncology, and direct Stanford's Surgical Oncology Fellowship program while...
To drive their growth, many tumors hijack nervous system signals, including those needed for brain plasticity. Stanford Medicine discoveries are opening a promising new branch of oncology research.
Stanford Cancer Institute members Ash Alizadeh, MD, PhD, and Max Diehn, MD, PhD, have developed several novel techniques for early detection of cancer that rely on blood-based liquid biopsies.
National guidelines for lung cancer screening are less effective for African Americans than for whites, Stanford study concludes. A risk-based analysis is more equitable and effective.
Small cell lung cancers often metastasize to the brain. A Stanford Medicine study shows they thrive there by emulating developing neurons and recruiting surrounding cells for protection.
The award will facilitate a clinical trial testing the safety of CAR-T cells — immune cells from patients’ own bodies that have been bioengineered to destroy cancer cells — used to treat a deadly brain cancer.
We spoke with Stanford Cancer Institute (SCI) leaders to learn about advances in breast cancer treatment, issues affecting survivors, and bridging the racial inequities gap.
The overarching goal of the Cancer Therapeutics Program is to foster collaboration across scientific and clinical disciplines in order to gain deeper insights into cancer’s underlying causes and develop more effective diagnostic, prognostic, and...
Physicians, researchers and other pacesetters describe some of the most promising pursuits in the medical field. In cancer, for instance: ‘Let’s kill the first cell, not the last cell.’
Stanford is excited to have 26 presenters at this year's ASH Annual Meeting & Exposition. The Stanford Cancer Institute will also be hosting a booth at this year's conference.
A molecular “snapshot” of a protein can be critical to understanding its function. Scientists at Stanford and NYU have published and investigated a new structure of the protein LAG-3 which could enable the development of new cancer treatments.
The new study found that an RNA-targeting CRISPR platform could tune immune cell metabolism without permanent genetic changes, potentially unveiling a relatively low-risk way to upgrade existing cell therapies for cancer.
The Office of Communication & Public Affairs is dedicated to sharing School of Medicine news with the media and helping journalists secure expert interviews, photographs and rich media for stories on medicine and health care.
